Home › Research › Tau biomarkers
Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders
Jie-Qiong Li, Yan-Lin Bi, Xue-Ning Shen, Hui-Fu Wang, Wei Xu, Chen-Chen Tan, Qiang Dong, Yan-Jiang Wang et al.. Translational neurodegeneration, 2020-11-23
Topic: Plasma and spinal-fluid biomarkers
The CSF α-synuclein levels correlated with AD-specific biomarkers, CSF total tau and phosphorylated tau levels, in 651 Chinese Han participants (training set). These positive correlations were replicated in the ADNI database (validation set). Using a longitudinal cohort from ADNI, the CSF α-synuclein concentrations were found to increase with disease severity. The CSF α-synuclein had high diagnostic accuracy for AD based on the "ATN" (amyloid, tau, neurodegeneration) system (A + T+ versus A - T - control) (area under the receiver operating characteristic curve, 0.84). Moreover, CSF α-synuclein predicted longitudinal hippocampus atrophy and conversion from MCI to AD dementia. CSF α-synuclein is associated with CSF tau levels and could predict neurodegeneration and clinical progression in non-demented elders. This finding indicates that CSF α-synuclein is a potentially useful early biomarker for AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Li, J.-Q., Bi, Y.-L., Shen, X.-N., Wang, H.-F., Xu, W., Tan, C.-C., et al. (2020). Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders. Translational neurodegeneration. https://doi.org/10.1186/s40035-020-00222-1
Vancouver
Li J.-Q, Bi Y.-L, Shen X.-N, Wang H.-F, Xu W, Tan C.-C, et al. Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders. Translational neurodegeneration. 2020. doi:10.1186/s40035-020-00222-1. PMID: 33228804.
BibTeX
@article{li2020-33228804,
author = {Li, Jie-Qiong and Bi, Yan-Lin and Shen, Xue-Ning and Wang, Hui-Fu and Xu, Wei and Tan, Chen-Chen and Dong, Qiang and Wang, Yan-Jiang and others},
title = {{Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders}},
journal = {Translational neurodegeneration},
year = {2020},
doi = {10.1186/s40035-020-00222-1},
pmid = {33228804},
url = {https://doi.org/10.1186/s40035-020-00222-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The CSF α-synuclein levels correlated with AD-specific biomarkers, CSF total tau and phosphorylated tau levels, in 651 Chinese Han participants (training set).
- These positive correlations were replicated in the ADNI database (validation set).
- Using a longitudinal cohort from ADNI, the CSF α-synuclein concentrations were found to increase with disease severity.
- The CSF α-synuclein had high diagnostic accuracy for AD based on the "ATN" (amyloid, tau, neurodegeneration) system (A + T+ versus A - T - control) (area under the receiver operating characteristic curve, 0.84).
- Moreover, CSF α-synuclein predicted longitudinal hippocampus atrophy and conversion from MCI to AD dementia.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 31 of the 56 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Translational neurodegeneration) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33228804) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 31 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 31 of the 56 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Tau biomarkers
Also tagged “neurofilament”
693 studies in the library carry the topic tag “neurofilament”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.